Large-scale screening for somatic mutations in lung cancer

The Lancet

Volumn 387, Issue 10026, 2016, Pages 1354-1356

  Rosell, Rafael ^a,b   Karachaliou, Niki ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PIK3CA PROTEIN; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; NEXT GENERATION SEQUENCING; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84954288742     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01125-3     Document Type: Note

References (15)

1. Z Chen, CM Fillmore, PS Hammerman et al. Non-small-cell lung cancers: a heterogeneous set of diseases Nat Rev Cancer 14 2014 535 546
2. R Rosell, E Carcereny, R Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
3. F Barlesi, J Mazieres, J-P Merlio for the Biomarkers France contributors Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Lancet 2016 published online Jan 14. http://dx.doi.org/10.1016/S0140-6736(16)00004-0
4. R Rosell, T Moran, C Queralt et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
5. R Rosell, TG Bivona, N Karachaliou Genetics and biomarkers in personalisation of lung cancer treatment Lancet 382 2013 720 731
6. RS Heist, JA Engelman SnapShot: non-small cell lung cancer Cancer Cell 21 2012 448.e2
7. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
8. PK Paik, A Drilon, PD Fan et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping Cancer Discov 5 2015 842 849
9. M Scheffler, M Bos, M Gardizi et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies Oncotarget 6 2015 1315 1326
10. Clinical Lung Cancer Genome Project (CLCGP) Network Genomic Medicine (NGM) A genomics-based classification of human lung tumors Sci Transl Med 5 2013 209ra153
11. K Konig, M Peifer, J Fassunke et al. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients J Thorac Oncol 10 2015 1049 1057
12. DR Gandara, PS Hammerman, ML Sos et al. Squamous cell lung cancer: from tumor genomics to cancer therapeutics Clin Cancer Res 21 2015 2236 2243
13. R Rosell, N Karachaliou, J Wolf et al. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy Lancet Respir Med 2 2014 966 968
14. MG Kris, BE Johnson, LD Berry et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 311 2014 1998 2006
15. S Matsumoto, K Tsuchihara, K Yoh et al. A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small lung cancers with rare driver mutations J Clin Oncol 32 suppl 2014 5s Abstract 11007.